Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer
Carregando...
Citações na Scopus
125
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
CARNIELLI, Carolina Moretto
MACEDO, Carolina Carneiro Soares
ROSSI, Tatiane De
GRANATO, Daniela Campos
RIVERA, Cesar
DOMINGUES, Romenia Ramos
PAULETTI, Bianca Alves
YOKOO, Sami
HEBERLE, Henry
BUSSO-LOPES, Ariane Fidelis
Citação
NATURE COMMUNICATIONS, v.9, article ID 3598, 17p, 2018
Resumo
Different regions of oral squamous cell carcinoma (OSCC) have particular histopathological and molecular characteristics limiting the standard tumor-node-metastasis prognosis classification. Therefore, defining biological signatures that allow assessing the prognostic outcomes for OSCC patients would be of great clinical significance. Using histopathology-guided discovery proteomics, we analyze neoplastic islands and stroma from the invasive tumor front (ITF) and inner tumor to identify differentially expressed proteins. Potential signature proteins are prioritized and further investigated by immunohistochemistry (IHC) and targeted proteomics. IHC indicates low expression of cystatin-B in neoplastic islands from the ITF as an independent marker for local recurrence. Targeted proteomics analysis of the prioritized proteins in saliva, combined with machine-learning methods, highlights a peptide-based signature as the most powerful predictor to distinguish patients with and without lymph node metastasis. In summary, we identify a robust signature, which may enhance prognostic decisions in OSCC and better guide treatment to reduce tumor recurrence or lymph node metastasis.
Palavras-chave
Referências
- Alfonso P, 2008, J PROTEOME RES, V7, P4247, DOI 10.1021/pr800152u
- Almangush A, 2015, INT J ORAL MAX SURG, V44, P143, DOI 10.1016/j.ijom.2014.10.004
- Arduino PG, 2008, J ORAL MAXIL SURG, V66, P1570, DOI 10.1016/j.joms.2007.12.024
- Barnes L., 2005, WHO CLASSIF TUMOUR, P163, DOI [10.1016/j.urology.2004.09.048, DOI 10.1016/J.UROLOGY.2004.09.048]
- Batista G.E.A.P.A., 2004, ACM SIGKDD EXPL NEWS, V6, P20, DOI 10.1145/1007730.1007735
- BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
- Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167
- Brandwein-Gensler M., 2010, AM J SURG PATHOL, V34, P1
- BRYNE M, 1992, J PATHOL, V166, P375, DOI 10.1002/path.1711660409
- BRYNE M, 1989, J ORAL PATHOL MED, V18, P432, DOI 10.1111/j.1600-0714.1989.tb01339.x
- Bu JQ, 2015, MED SCI MONITOR, V21, P2275, DOI 10.12659/MSM.893925
- Costa LCMC, 2015, J APPL ORAL SCI, V23, P169, DOI 10.1590/1678-775720140187
- Carvalho AL, 2005, OTOLARYNG HEAD NECK, V132, P862, DOI 10.1016/j.otohns.2005.01.034
- Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
- Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001
- Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041
- Chi LM, 2009, MOL CELL PROTEOMICS, V8, P1453, DOI 10.1074/mcp.M800460-MCP200
- Chung LC, 2012, AM J PHYSIOL-CELL PH, V302, pC676, DOI 10.1152/ajpcell.00180.2011
- Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
- Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
- Curry JM, 2014, SEMIN ONCOL, V41, P217, DOI 10.1053/j.seminoncol.2014.03.003
- da Silva SD, 2015, ONCOTARGET, V6, P21950, DOI 10.18632/oncotarget.4277
- da Silva SD, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00149
- DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
- Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
- Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068
- Fang BA, 2014, BBA-REV CANCER, V1845, P1, DOI 10.1016/j.bbcan.2013.11.002
- Feldman AS, 2009, CLIN CANCER RES, V15, P1024, DOI 10.1158/1078-0432.CCR-08-1143
- Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
- Flores IL, 2016, CLIN SCI, V130, P785, DOI 10.1042/CS20150646
- Gallien S, 2011, J MASS SPECTROM, V46, P298, DOI 10.1002/jms.1895
- Ganly I, 2012, CANCER-AM CANCER SOC, V118, P101, DOI 10.1002/cncr.26229
- Greenberg JS, 2003, CANCER, V98, P508, DOI 10.1002/cncr.11526
- Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
- Harris TM, 2015, ARCH PATHOL LAB MED, V139, P494, DOI 10.5858/arpa.2014-0131-OA
- Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
- Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176
- Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091
- Hwang TL, 2006, PROTEOMICS, V6, P2259, DOI 10.1002/pmic.200500345
- Jensen DH, 2015, J PATHOL, V236, P505, DOI 10.1002/path.4550
- Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576
- Kawahara R, 2016, PROTEOMICS, V16, P159, DOI 10.1002/pmic.201500224
- Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11906
- Lagani V., 2016, J STAT SOFTW, V25
- Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61
- Larsen SR, 2009, J ORAL PATHOL MED, V38, P657, DOI 10.1111/j.1600-0714.2009.00797.x
- Levicar N, 2002, CANCER DETECT PREV, V26, P42, DOI 10.1016/S0361-090X(02)00015-6
- Lu JG, 2011, J CANCER RES CLIN, V137, P1613, DOI 10.1007/s00432-011-1024-y
- MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
- Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
- Marakalala MJ, 2016, NAT MED, V22, P531, DOI 10.1038/nm.4073
- McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
- Mehanna H, 2016, NEW ENGL J MED, V374, P1
- Meng WX, 2014, CANCER RES, V74, P2306, DOI 10.1158/0008-5472.CAN-13-2275
- Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329
- Oi N, 2017, CARCINOGENESIS, V38, P728, DOI 10.1093/carcin/bgx049
- Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
- Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261
- Rodrigues PC, 2015, ONCOL LETT, V9, P667, DOI 10.3892/ol.2014.2763
- Romanska HM, 2013, ORAL ONCOL, V49, P224, DOI 10.1016/j.oraloncology.2012.09.013
- Sabatelli P, 2001, MATRIX BIOL, V20, P475, DOI 10.1016/S0945-053X(01)00160-3
- Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
- Salo T, 2014, EXP CELL RES, V325, P58, DOI 10.1016/j.yexcr.2013.12.029
- Sawazaki-Calone I, 2015, ORAL DIS, V21, P755, DOI 10.1111/odi.12343
- Schaaij-Visser TBM, 2009, CLIN CANCER RES, V15, P7666, DOI 10.1158/1078-0432.CCR-09-2134
- Scully C, 2009, ORAL ONCOL, V45, P301, DOI 10.1016/j.oraloncology.2009.01.004
- Sharma Mohit, 2013, J Oral Maxillofac Pathol, V17, P240, DOI 10.4103/0973-029X.119740
- Sundquist E, 2017, BRIT J CANCER, V116, P640, DOI 10.1038/bjc.2016.455
- Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
- Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
- Turk V, 2008, FRONT BIOSCI-LANDMRK, V13, P5406, DOI 10.2741/3089
- Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902
- van der Waal I, 2013, MED ORAL PATOL ORAL, V18, pE33, DOI 10.4317/medoral.18486
- Villen J, 2008, NAT PROTOC, V3, P1630, DOI 10.1038/nprot.2008.150
- Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
- Waisberg J, 2014, ANTICANCER RES, V34, P5599
- Wang YH, 2015, CANCER BIOMARK, V15, P213, DOI 10.3233/CBM-150464
- Winck FV, 2015, SCI REP-UK, V5, DOI 10.1038/srep16305
- Xie N, 2015, J ORAL PATHOL MED, V44, P266, DOI 10.1111/jop.12242
- Zhang J, 2016, ONCOL RES, V24, P487, DOI 10.3727/096504016X14685034103752